When you take a blood test, the result is a snapshot — accurate for that moment, irrelevant a year later. When you sequence your entire genome, the result is permanent. Your DNA sequence doesn't change. But the science that interprets it does — and that's what makes whole genome sequencing fundamentally different from any other health test.
Your data is fixed. The science is not.
Every month, researchers around the world publish new findings linking genetic variants to diseases, drug responses, and health conditions. The ClinVar database — the primary public archive of variant-disease relationships — adds thousands of new entries per year. The pace is accelerating as larger genomic datasets become available for population-scale analysis.
This means a variant in your genome that is classified as a "variant of uncertain significance" (VUS) today might be reclassified as pathogenic next year — when enough evidence accumulates from clinical studies. Conversely, a variant that appeared concerning might be downgraded as more population data becomes available.
The key question is: does your test provider re-analyze your data when these updates happen?
Why most tests are frozen in time
Consumer genotyping tests — the kind offered by 23andMe, AncestryDNA, and similar services — read a pre-selected set of genetic positions on a chip. The report you receive reflects what was known about those specific positions on the day the chip was designed. If science discovers something new about a variant that wasn't on the chip, or reclassifies a variant that was, your results don't update — because the underlying data is incomplete.
Even some clinical tests have this limitation. Targeted gene panels read only the genes included in the panel. If future research identifies a clinically important variant in a gene that wasn't on your panel, you'd need a new test to detect it.
How whole genome reanalysis works
Whole genome sequencing reads every position in your genome — approximately 6.4 billion base pairs. This means your data file is complete from day one. Nothing was left out. Nothing needs to be re-collected.
When new variant-disease associations are published and clinically validated, the raw data from your original sequencing can be re-analyzed against updated databases. New clinically significant findings that weren't known at the time of your original test can be surfaced — without requiring a blood draw, a new kit, or a new test.
At Dante Labs, this reanalysis happens automatically through the Genome Manager platform. When we validate new variant-disease associations through our clinical review process, your reports are updated to reflect the latest science. You receive notification of any clinically relevant changes.
What this looks like in practice
Consider a real-world example: in the years since ClinVar began tracking variant classifications, approximately 7% of all classified variants have been reclassified at least once as new evidence emerged. Some VUS variants were upgraded to pathogenic. Some likely pathogenic variants were downgraded. These reclassifications have direct clinical consequences — they change whether screening is recommended, which medications are appropriate, and which family members should be tested.
With a complete genome dataset, these reclassifications are automatically applied to your reports. With an incomplete dataset — anything less than whole genome sequencing — they may not be, either because the relevant variant wasn't tested or because the provider doesn't offer reanalysis.
The economics of sequencing once
There's a practical argument, too. Whole genome sequencing costs a fraction of what it did five years ago — and the trend continues downward. But the calculus isn't just about today's price. It's about the total lifetime cost of genetic information.
If you take a targeted panel test today and a different panel test next year — because your clinical question changed or because new genes were added to the panel — you're paying twice for incomplete views of the same genome. Whole genome sequencing captures everything once. Every future question is answered from the same dataset.
The bottom line
Your genome is the only health test that gets more valuable after you take it. Not because your DNA changes — it doesn't. Because the science that reads it never stops advancing. The only requirement is that your original test captured everything. That's exactly what whole genome sequencing does.
Learn more about the Dante Labs Genome Test →
Get new posts from Dante Labs
Genomics insights, product updates, and clinical perspectives — delivered to your inbox.
